Skip to main content
. 2011 May 19;154(3):387–397. doi: 10.1111/j.1365-2141.2011.08720.x

Fig 1.

Fig 1

Yearly frequency of most common (≥5% overall) investigator-assessed drug-related AEs after the start of deferasirox. *Reported as an AE by the investigator.